The Capsule of Cryptococcus neoformans Reduces T-Lymphocyte Proliferation by Reducing Phagocytosis, Which Can Be Restored with Anticapsular Antibody

ABSTRACT Cell-mediated immunity is critical for the host defense toCryptococcus neoformans, as demonstrated by numerous animal studies and the prevalence of the infection in AIDS patients. Previous studies have established that the polysaccharide capsule contributes to the virulence of C. neoformans by suppressing T-lymphocyte proliferation, which reflects the clonal expansion of T lymphocytes that is a hallmark of cell-mediated immunity. The present studies were performed to identify the major mechanism by which polysaccharide impairs lymphocyte proliferation, since capsular polysaccharide has the potential to affect the development of T-lymphocyte responses by stimulating production of interleukin-10 (IL-10), inhibiting phagocytosis, and inducing shedding of cell surface receptors. We demonstrate that polysaccharide inhibits lymphocyte proliferation predominantly by blocking uptake of C. neoformans, which is crucial for subsequent lymphocyte proliferation. In addition, we show that polysaccharide did not suppress lymphocyte proliferation via an IL-10-dependent mechanism, nor did it affect critical surface receptor interactions on the T cell or antigen-presenting cell. Having established that polysaccharide impairs phagocytosis, we performed studies to determine whether opsonization with human serum or with anticapsular antibody could reverse this effect. Impaired uptake and lymphocyte proliferation that were induced by polysaccharide can be enhanced through opsonization with monoclonal antibodies or human serum, suggesting that antipolysaccharide antibodies might enhance the host defense by restoring uptake of the organism and subsequent presentation to T lymphocytes. These studies support the therapeutic potential of stimulating cell-mediated immunity to C. neoformans with anticapsular antibody.

[1]  A. Casadevall,et al.  Specific Antibody to Cryptococcus neoformans Alters Human Leukocyte Cytokine Synthesis and Promotes T-Cell Proliferation , 1998, Infection and Immunity.

[2]  F. Bistoni,et al.  Encapsulation of Cryptococcus neoformans with Glucuronoxylomannan Inhibits the Antigen-Presenting Capacity of Monocytes , 1998, Infection and Immunity.

[3]  F. Bistoni,et al.  Regulatory role of exogenous IL‐10 in the development of immune response versus Cryptococcus neoformans , 1997, Clinical and experimental immunology.

[4]  A. Casadevall,et al.  T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Casadevall,et al.  Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. , 1997, Journal of immunology.

[6]  M. Burdick,et al.  Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. , 1996, Journal of immunology.

[7]  L. Pirofski,et al.  Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies , 1996, Infection and immunity.

[8]  F. Bistoni,et al.  Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes , 1996, Infection and immunity.

[9]  S. Devi Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. , 1996, Vaccine.

[10]  J. Murphy,et al.  Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils. , 1996, The Journal of clinical investigation.

[11]  J. Verhoef,et al.  Quantitative analysis of phagocytosis and killing of Cryptococcus neoformans by human peripheral blood mononuclear cells by flow cytometry , 1995, Clinical and diagnostic laboratory immunology.

[12]  T. Beccari,et al.  Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes , 1995, Infection and immunity.

[13]  L. Pirofski,et al.  Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine , 1995, Infection and immunity.

[14]  E. A. Havell,et al.  Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice , 1995, Infection and immunity.

[15]  M. Puliti,et al.  Biomolecular events involved in anticryptococcal resistance in the brain , 1995, Infection and Immunity.

[16]  L. Pirofski,et al.  Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV− individuals , 1995, Clinical and experimental immunology.

[17]  A. Casadevall,et al.  Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. , 1995, Journal of immunology.

[18]  A. Casadevall,et al.  Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages , 1995, Infection and immunity.

[19]  A. Casadevall,et al.  Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell , 1995, The Journal of experimental medicine.

[20]  F. Bistoni,et al.  Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages , 1994, Clinical and experimental immunology.

[21]  T. Kozel,et al.  Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan , 1994, Infection and immunity.

[22]  A. Casadevall,et al.  Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B , 1994, Antimicrobial Agents and Chemotherapy.

[23]  T. Kozel,et al.  Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans , 1993, Infection and immunity.

[24]  C. Mody,et al.  Effect of polysaccharide capsule and methods of preparation on human lymphocyte proliferation in response to Cryptococcus neoformans , 1993, Infection and immunity.

[25]  M. de Carli,et al.  Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. , 1993, Journal of immunology.

[26]  R. Coker Cryptococcal Infection in AIDS , 1992, International journal of STD & AIDS.

[27]  G. Bancroft,et al.  Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses , 1991, Infection and immunity.

[28]  C G Figdor,et al.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes , 1991, The Journal of experimental medicine.

[29]  Devi,et al.  Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity , 1991, Infection and immunity.

[30]  R. Maziarz,et al.  Killing of Cryptococcus neoformans by human peripheral blood mononuclear cells stimulated in culture. , 1991, The Journal of infectious diseases.

[31]  S. Levitz,et al.  Binding of Cryptococcus neoformans by human cultured macrophages. Requirements for multiple complement receptors and actin. , 1991, The Journal of clinical investigation.

[32]  S. Levitz,et al.  Growth inhibition of Cryptococcus neoformans by cultured human monocytes: role of the capsule, opsonins, the culture surface, and cytokines , 1990, Infection and immunity.

[33]  F. Dromer,et al.  Role of IgG and complement component C5 in the initial course of experimental cryptococcosis. , 1989, Clinical and experimental immunology.

[34]  T. Kozel,et al.  Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific for the capsular polysaccharide , 1989, Infection and immunity.

[35]  T. Kozel,et al.  Strain variation in phagocytosis of Cryptococcus neoformans: dissociation of susceptibility to phagocytosis from activation and binding of opsonic fragments of C3 , 1988, Infection and immunity.

[36]  S. Levitz,et al.  Differential stimulation of murine resident peritoneal cells by selectively opsonized encapsulated and acapsular Cryptococcus neoformans , 1988, Infection and immunity.

[37]  I. Grant,et al.  Fungal infections in AIDS. Cryptococcosis. , 1988, Infectious disease clinics of North America.

[38]  W. Dismukes Cryptococcal meningitis in patients with AIDS. , 1988, The Journal of infectious diseases.

[39]  C. Mody,et al.  Cyclosporin A inhibits the growth of Cryptococcus neoformans in a murine model , 1988, Infection and immunity.

[40]  T. Kozel,et al.  Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide , 1987, Infection and immunity.

[41]  T. G. Mitchell,et al.  Strain variation in composition and molecular size of the capsular polysaccharide of Cryptococcus neoformans serotype A , 1986, Infection and immunity.

[42]  T. Kozel,et al.  Binding of cryptococcal polysaccharide to Cryptococcus neoformans , 1984, Infection and immunity.

[43]  J. Repine,et al.  Opsonic requirements for the uptake of Cryptococcus neoformans by human polymorphonuclear leukocytes and monocytes. , 1982, The Journal of infectious diseases.

[44]  E. Jacobson,et al.  Genetic and phenotypic characterization of capsule mutants of Cryptococcus neoformans , 1982, Journal of bacteriology.

[45]  T. Kozel,et al.  Opsonization of Cryptococcus neoformans by human immunoglobulin G: role of immunoglobulin G in phagocytosis by macrophages , 1979, Infection and immunity.

[46]  T. Kozel Non-encapsulated variant of Cryptococcus neoformans. II. Surface receptors for cryptococcal polysaccharide and their role in inhibition of phagocytosis by polysaccharide , 1977, Infection and immunity.

[47]  T. Kozel,et al.  Inhibition of phagocytosis by cryptococcal polysaccharide: dissociation of the attachment and ingestion phases of phagocytosis , 1976, Infection and immunity.

[48]  T. G. Mitchell,et al.  In Vitro Phagocytosis and Intracellular Fate of Variously Encapsulated Strains of Cryptococcus neoformans , 1972, Infection and immunity.

[49]  T. Kozel,et al.  Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide , 1971, Infection and immunity.

[50]  J. Bennett,et al.  Serologic Grouping of Cryptococcus neoformans , 1968, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.